Peer-reviewed veterinary case report
Chewable tablet safe and effective for treating Angiostrongylus
By Lloyd, Anne et al.·Published in Veterinary parasitology·2026·Zoetis·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Safety and efficacy assessment of a chewable tablet containing sarolaner, moxidectin, and pyrantel in the treatment of Angiostrongylus vasorum in dogs.
- Species:
- dog
Plain-English summary
A group of dogs infected with a parasite called Angiostrongylus vasorum were treated with a chewable tablet containing sarolaner, moxidectin, and pyrantel. This treatment was very effective, reducing the number of adult worms by over 98% after just one dose. In a field study involving client-owned dogs, 90% of the treated dogs showed a significant decrease in parasite larvae within 30 days, and nearly all were clear of the infection by 60 days. The chewable tablet was well tolerated, making it a safe option for treating this serious infection in dogs.
People also search for: dog Angiostrongylus vasorum treatment · chewable tablet for dog parasites · dog parasite infection symptoms
Abstract
Angiostrongylosis, caused by Angiostrongylus vasorum, is an important clinical disease in dogs in Europe with infection transmitted through infected snails and slugs which function as intermediate hosts. Previous studies demonstrated the preventive efficacy of a monthly administration of moxidectin in combination with sarolaner and pyrantel (Simparica Trio® chewable tablet (SMP); Zoetis). An experimental infection study and a field study were conducted to evaluate the efficacy and safety of SMP for the treatment of infections with adult stages of A. vasorum in dogs. The experimental study evaluated the efficacy of a single (n = 7 dogs) or repeated dose (n = 8 dogs) of SMP at the minimum recommended dose of 1.2 mg/kg sarolaner, 0.024 mg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) administered as a chewable tablet. against an induced infection with 200 (±10) L3 A. vasorum at least 63 days prior to treatment on Day 0, compared to a placebo control product (n = 8 dogs). Efficacy was determined based on adult worm counts 56 or 57 days after treatment. The field study at veterinary practices in Italy and Denmark evaluated the efficacy and safety of SMP in client-owned dogs (n = 66). Advocate® Spot On (100 mg/mL (minimum 10 mg/kg) imidacloprid + 25 mg/mL (minimum 2.5 mg/kg) moxidectin from Elanco Animal Health, n = 37) was used as the control product. Treatment was administered on Day 0 and repeated on Day 30 if the dog was still positive for A. vasorum larvae. Faecal samples were collected and analyzed with the modified Baermann method in-between scheduled visits. In the experimental study the percentage reduction in geometric mean adult worm counts compared to the placebo-treated group was 98.3 % (P < 0.0001) after a single dose of SMP and 99.6 % (P < 0.0001) after two doses. In the field study, faecal larvae counts were reduced by 90 % or more in 90.9 % of the dogs in the SMP-treated group at Day 30 and in 98.5 % of dogs at Day 60. Compared to the pre-treatment faecal larvae counts a geometric mean percent reduction of 96.7 % was observed on Day 30 and 99.1 % on Day 60 in the SMP treated group. Both in the experimental and in the field study, SMP as a chewable tablet was well tolerated and resulted in a high efficacy against adult A. vasorum infections after a single treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41259838/